Kaan Kavaklı - Concepedia

Author

Kaan Kavaklı

Also Known As

K Kavakli, K. KAVAKLI, K. KAVAKLİ, K. Kavakli, KAAN KAVAKLI, KAVAKLI, Kuthan, Kaan KAVAKLI, Kaan Kavakli, Kaan Kavakli Md, Kaan Kavaklı

163

Publications

Citations

H-Index

Concepts

All Affiliations

Ege University Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico University of Milan Children's Hospital of Los Angeles Istanbul University

About

Kaan Kavaklı is an author at Ege University specializing in medicine, hematology, and pediatrics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	354
2	Public Health	3	3	112
3	Health Sciences	2	2	79
4	Social Sciences	1	1	31
5	Allergy	1	1	59

Kaan Kavaklı

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A Flora Peyvandi, Pier Mannuccio Mannucci, Isabella Garagiola, New England Journal of Medicine	2016	483
Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors Cindy Leissinger, A. Gringeri, Bülent Antmen, New England Journal of Medicine	2011	219
Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results Amy D. Shapiro, Pantep Angchaisuksiri, Jan Astermark, Blood	2019	145
Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies Paul Monagle, Anthonie W.A. Lensing, Kirstin Thelen, The Lancet Haematology ThrombosisPulmonary EmbolismVenous DiseaseVenous ThrombosisCardiovascular Disease	2019	74
Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B Adam Cuker, Kaan Kavaklı, Laurent Frenzel, New England Journal of Medicine	2024	66
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial Steven W. Pipe, Peter W. Collins, Christophe Dhalluin, Blood ThrombosisHealth SciencesPediatric HematologyImmunologyHematology	2023	65
Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity Johnny Mahlangu, Karin Weldingh, Steven R. Lentz, Journal of Thrombosis and Haemostasis Clinical ImmunologyMolecular ImmunologyImmunogeneticsVatreptacog AlfaAllergy	2015	59
Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data Hermann Eichler, Pantep Angchaisuksiri, Kaan Kavaklı, Haemophilia	2018	37
Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients Toshko Lissitchkov, Bella Madan, Claudia Djambas Khayat, Journal of Thrombosis and Haemostasis	2019	34
Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial Erich Vinícius De Paula, Kaan Kavaklı, Johnny Mahlangu, Journal of Thrombosis and Haemostasis ThrombosisMedicineHematologyHemostasisPharmacotherapy	2011	33

Page 1